Benzhydrocodone is a benzylic prodrug of hydrocodone. It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse. Benzhydrocodone is indicated for... Benzhydrocodone is indicated for use in the short-term management of pain.
- Mechanism
- Curator reviewed
Benzyhydrocodone is not reported to have pharmacological activity of its own and it not present in the plasma at detectable concentrations. Its active metabolite, hydrocodone is a mu-opioid receptor agonist.
- Primary indication
- Benzyhydrocodone is indicated, in combination with acetaminophen, for the short-term management of acute pain requiring opioid therapy.Curator reviewed · 1 structured indication
- Formula / weight
- C25H25NO4 · 403.478 g/mol (avg)
- First approval
- United States, 2018
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
VPMRSLWWUXNYRY-NDOYXKHWSA-NSMILES[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CC=C2OC(=O)C1=CC=CC=C1Targets
What you can answer from here — as of September 16, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Benzhydrocodone, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account